{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:55:17Z","timestamp":1793433317935,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ferritin levels are used to make decisions on therapy of iron deficiency in patients with chronic kidney disease (CKD). Hyperferritinaemia, common among patients with CKD from the Northern Territory (NT) of Australia, makes use of ferritin levels as per clinical guidelines challenging.<\/jats:p>\n                    <jats:p>No gold standard assay exists for measuring ferritin levels. Significant variability between results from different assays creates challenges for clinical decision-making regarding iron therapy. In the NT, different laboratories use different methods. In 2018, Territory Pathology changed the assay from Abbott ARCHITECT i1000 (AA) to Ortho-Clinical Diagnostics Vitros 7600 (OCD). This was during the planning of the INtravenous iron polymaltose for First Nations Australian patients with high FERRitin levels on haemodialysis (INFERR) clinical trial. The trial design was based on AA assay ferritin levels. We compared the two assays\u2019 level of agreement in measuring ferritin levels in CKD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Samples from INFERR clinical trial participants were analysed. Other samples from patients whose testing were completed the same day on OCD analyzers and run within 24\u00a0h on AA analyzers were added to ensure wide range of ferritin levels, adding statistical strength to the comparison. Ferritin levels from both assays were compared using Pearson\u2019s correlation, Bland\u2013Altman, Deming and Passing-Bablok regression analyses. Differences between sample types, plasma and serum were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-eight and 111 (179) samples from different patients from Central Australia and Top End of Australia, respectively, were analyzed separately and in combination. The ferritin levels ranged from 3.1\u00a0\u00b5g\/L to 3354\u00a0\u00b5g\/L and 3\u00a0\u00b5g\/L to 2170\u00a0\u00b5g\/L for AA and OCD assays respectively. Using Bland\u2013Altman, Deming and Passing-Bablok regression methods for comparison, ferritin results were consistently 36% to 44% higher with AA than OCD assays. The bias was up to 49%. AA ferritin results were the same in serum and plasma. However, OCD ferritin results were 5% higher in serum than plasma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>When making clinical decisions, using ferritin results from the same assay in patients with CKD is critical. If the assay is changed, it is essential to assess agreement between results from the new and old assays. Further studies to harmonize ferritin assays are required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-023-03255-6","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T17:01:24Z","timestamp":1688144484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of two ferritin assay platforms to assess their level of agreement in measuring serum and plasma ferritin levels in patients with chronic kidney disease"],"prefix":"10.1186","volume":"24","author":[{"given":"Sandawana William","family":"Majoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asanga","family":"Abeyaratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Kiran","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajiv","family":"Cherian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetha","family":"Rathnayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Ashford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Hocking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Cain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"McFarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Damian","family":"Lawton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Barzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Cass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"issue":"Suppl 1","key":"3255_CR1","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1111\/hdi.12556","volume":"21","author":"AE Gaweda","year":"2017","unstructured":"Gaweda AE. Markers of iron status in chronic kidney disease. Hemodial Int. 2017;21(Suppl 1):S21-s27.","journal-title":"Hemodial Int"},{"issue":"4","key":"3255_CR2","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/hdi.12173","volume":"18","author":"SW Majoni","year":"2014","unstructured":"Majoni SW, Ellis J-A, Hall H, Abeyaratne A, Lawton PD. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia. Hemodial Int. 2014;18(4):740\u201350.","journal-title":"Hemodial Int"},{"key":"3255_CR3","doi-asserted-by":"publisher","first-page":"5490963","DOI":"10.1155\/2017\/5490963","volume":"2017","author":"SW Majoni","year":"2017","unstructured":"Majoni SW, Lawton PD, Barzi F, Cass A, Hughes JT. Assessing the Association between Serum Ferritin, Transferrin Saturation, and C-Reactive Protein in Northern Territory Indigenous Australian Patients with High Serum Ferritin on Maintenance Haemodialysis. Int J Nephrol. 2017;2017:5490963.","journal-title":"Int J Nephrol"},{"issue":"2","key":"3255_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ekir.2020.10.035","volume":"6","author":"SW Majoni","year":"2021","unstructured":"Majoni SW, Lawton PD, Rathnayake G, Barzi F, Hughes JT, Cass A. Narrative Review of Hyperferritinemia, Iron Deficiency, and the Challenges of Managing Anemia in Aboriginal and Torres Strait Islander Australians With CKD. Kidney Int Rep. 2021;6(2):501\u201312.","journal-title":"Kidney Int Rep"},{"issue":"9","key":"3255_CR5","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1210\/me.2014-1230","volume":"28","author":"A Schonbrunn","year":"2014","unstructured":"Schonbrunn A. Editorial: Antibody Can Get It Right: Confronting Problems of Antibody Specificity and Irreproducibility. Mol Endocrinol. 2014;28(9):1403\u20137.","journal-title":"Mol Endocrinol"},{"issue":"1","key":"3255_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/ki.2008.526","volume":"75","author":"BA Ford","year":"2009","unstructured":"Ford BA, Coyne DW, Eby CS, Scott MG. Variability of ferritin measurements in chronic kidney disease; implications for iron management. Kidney Int. 2009;75(1):104\u201310.","journal-title":"Kidney Int"},{"issue":"5","key":"3255_CR7","doi-asserted-by":"publisher","first-page":"e0196576","DOI":"10.1371\/journal.pone.0196576","volume":"13","author":"MN Garcia-Casal","year":"2018","unstructured":"Garcia-Casal MN, Pe\u00f1a-Rosas JP, Urrechaga E, Escanero JF, Huo J, Martinez RX, Lopez-Perez L. Performance and comparability of laboratory methods for measuring ferritin concentrations in human serum or plasma: A systematic review and meta-analysis. PLoS ONE. 2018;13(5):e0196576.","journal-title":"PLoS ONE"},{"issue":"4","key":"3255_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1515\/CCLM.2002.059","volume":"40","author":"A Hamwi","year":"2002","unstructured":"Hamwi A, Endler G, Rubi K, Wagner O, Endler AT. Reference values for a heterogeneous ferritin assay and traceability to the 3rd International Recombinant Standard for Ferritin (NIBSC code 94\/572). Clin Chem Lab Med. 2002;40(4):365\u201370.","journal-title":"Clin Chem Lab Med"},{"key":"3255_CR9","unstructured":"Organization WH: WHO guideline on use of ferritin concentrations to assess iron status in populations: World Health Organization; 2020."},{"issue":"1","key":"3255_CR10","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1186\/s13063-021-05854-w","volume":"22","author":"SW Majoni","year":"2021","unstructured":"Majoni SW, Nelson J, Germaine D, Hoppo L, Long S, Divakaran S, Turner B, Graham J, Cherian S, Pawar B, et al. INFERR-Iron infusion in haemodialysis study: INtravenous iron polymaltose for First Nations Australian patients with high FERRitin levels on haemodialysis\u2014a protocol for a prospective open-label blinded endpoint randomised controlled trial. Trials. 2021;22(1):868.","journal-title":"Trials"},{"issue":"11","key":"3255_CR11","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","volume":"29","author":"IC Macdougall","year":"2014","unstructured":"Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Nolen JG, Roger SD. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol, Dial, Transplant. 2014;29(11):2075\u201384.","journal-title":"Nephrol, Dial, Transplant"},{"key":"3255_CR12","doi-asserted-by":"crossref","unstructured":"Ji Y, Faddy H, Hyland C, Flower R: A PLASMA FERRITIN IS NOT ALWAYS A SERUM FERRITIN. Pathology - Journal of the RCPA 2015, 47.","DOI":"10.1097\/01.PAT.0000461584.81641.2c"},{"key":"3255_CR13","unstructured":"National Association of Testing Authorities (NATA) in Australia [https:\/\/nata.com.au\/]"},{"key":"3255_CR14","unstructured":"The Royal College of Pathologists of Australasia Quality Assurance Programs [https:\/\/rcpaqap.com.au\/]"},{"key":"3255_CR15","unstructured":"NCSS 2019 Statistical Software (2019). NCSS LK U U, ncss.com\/software\/ncss,: Bland-Altman Plot and Analysis. In.: NCSS Statistical Software; 2019."},{"key":"3255_CR16","unstructured":"NCSS 2019 Statistical Software (2019). NCSS LK U, USA, ncss.com\/software\/ncss,: Deming Regression. In.: NCSS Statistical Software; 2019."},{"key":"3255_CR17","unstructured":"NCSS 2019 Statistical Software (2019). NCSS LK, Utah, USA, ncss.com\/software\/ncss: Passing-Bablok Regression for Method Comparison. In.: NCSS Statistical Software; 2019."},{"issue":"1","key":"3255_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.11613\/BM.2011.010","volume":"21","author":"L Bili\u0107-Zulle","year":"2011","unstructured":"Bili\u0107-Zulle L. Comparison of methods: Passing and Bablok regression. Biochem Med (Zagreb). 2011;21(1):49\u201352.","journal-title":"Biochem Med (Zagreb)"},{"issue":"1","key":"3255_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4103\/aca.ACA_157_18","volume":"22","author":"P Mishra","year":"2019","unstructured":"Mishra P, Pandey CM, Singh U, Gupta A, Sahu C, Keshri A. Descriptive statistics and normality tests for statistical data. Ann Card Anaesth. 2019;22(1):67\u201372.","journal-title":"Ann Card Anaesth"},{"issue":"7","key":"3255_CR20","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1440-1681.2010.05376.x","volume":"37","author":"J Ludbrook","year":"2010","unstructured":"Ludbrook J. Linear regression analysis for comparing two measurers or methods of measurement: but which regression? Clin Exp Pharmacol Physiol. 2010;37(7):692\u20139.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"1","key":"3255_CR21","first-page":"13","volume":"39","author":"D Ayan","year":"2020","unstructured":"Ayan D, Soylemez S. Measuring plasma ferritin levels with two different methods: A comparison of Roche Cobas e601 versus Roche Cobas c501 (integrated modular system Roche Cobas 6000). J Med Biochem. 2020;39(1):13\u20138.","journal-title":"J Med Biochem"},{"issue":"8","key":"3255_CR22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.31080\/ASMS.2019.03.0364","volume":"3","author":"Nermin Dindar Badem","year":"2019","unstructured":"Nermin Dindar Badem. Comparison of Ferritin Measurement Performance Through Immunoturbidimetric and Chemiluminescence Methods in Patients with Critical Ferritin Levels. Acta Scientific Medical Sciences. 2019;3(8):160\u20138.","journal-title":"Acta Scientific Medical Sciences"},{"issue":"1","key":"3255_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1515\/cclm-2016-0421","volume":"55","author":"CD Karakochuk","year":"2017","unstructured":"Karakochuk CD, Whitfield KC, Rappaport AI, Barr SI, Vercauteren SM, McLean J, Hou K, Talukder A, Houghton LA, Bailey KB, et al. Comparison of four immunoassays to measure serum ferritin concentrations and iron deficiency prevalence among non-pregnant Cambodian women and Congolese children. Clinical Chemistry and Laboratory Medicine (CCLM). 2017;55(1):65\u201372.","journal-title":"Clinical Chemistry and Laboratory Medicine (CCLM)"},{"key":"3255_CR24","doi-asserted-by":"crossref","unstructured":"Dahman LSB, Sumaily KM, Sabi EM, Hassan MA, Thalab AMB, Sayad AS, Kolaib SMB, Alhadhrmi FM: A Comparative Study for Measuring Serum Ferritin Levels with Three Different Laboratory Methods: Enzyme-Linked Immunosorbent Assay versus Cobas e411 and Cobas Integra 400 Methods. Diagnostics (Basel) 2022, 12(2).","DOI":"10.3390\/diagnostics12020320"},{"key":"3255_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000485704","volume":"196","author":"D Kamei","year":"2018","unstructured":"Kamei D, Mineshima M, Tsukada M, Miwa N, Hanafusa N, Tsuchiya K. Ferritin: Diversity and Management of Ferritin Measurement Methods. Contrib Nephrol. 2018;196:83\u20137.","journal-title":"Contrib Nephrol"},{"issue":"3","key":"3255_CR26","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.pathol.2021.06.123","volume":"54","author":"KW Choy","year":"2022","unstructured":"Choy KW, Sezgin G, Wijeratne N, Calleja J, Liwayan R, Rathnayake G, McFarlane R, McNeil A, Doery JCG, Lu Z, et al. Assessment of analytical bias in ferritin assays and impact on functional reference limits. Pathology. 2022;54(3):302\u20137.","journal-title":"Pathology"},{"issue":"30","key":"3255_CR27","first-page":"515","volume":"108","author":"R Kwiecien","year":"2011","unstructured":"Kwiecien R, Kopp-Schneider A, Blettner M. Concordance analysis: part 16 of a series on evaluation of scientific publications. Dtsch Arztebl Int. 2011;108(30):515\u201321.","journal-title":"Dtsch Arztebl Int"},{"issue":"9","key":"3255_CR28","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1093\/clinchem\/hvac099","volume":"68","author":"F Braga","year":"2022","unstructured":"Braga F, Pasqualetti S, Frusciante E, Borrillo F, Chibireva M, Panteghini M. Harmonization Status of Serum Ferritin Measurements and Implications for Use as Marker of Iron-Related Disorders. Clin Chem. 2022;68(9):1202\u201310.","journal-title":"Clin Chem"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03255-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03255-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03255-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T17:01:50Z","timestamp":1688144510000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03255-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3255"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03255-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2867389\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]},"assertion":[{"value":"27 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided informed consent and the study was performed in accordance with the Declaration of Helsinki. Full ethics approval was obtained to perform the study in the Top End by the NT Health and Menzies School of Health Research\u00a0Human Research Ethics Committee (HREC Reference Number: 2021\u20134124) and in Central Australia by the Central Australian Human Research Ethics Committee (CAHREC) (reciprocal ethical approval HREC Reference Number: 2021\u20134124). Research governance approval was obtained for both the Top End and Central Australia by the NT health Research Governance office (RGO) (RGO NT Health SSA: EFILE2021\/26937).The INFERR clinical trial has full ethics approval by NT Health and Menzies School of Health Research Human Research Ethics Committee (HREC Reference Number: 2019\u20133536 and Central Australia Human Research Committee (CAHREC Reference Number: CA-19\u20133567). The trial also has full NT health Research Governance office approval (RGO NT Health SSA: EFILE2020\/1471). This trial is registered with The Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12620000705987. Registered 29 June 2020.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"198"}}